中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

经颈静脉肝内门体分流术治疗原发性胆汁性肝硬化门静脉高压的效果及安全性

张玮 诸葛宇征 张明 贺奇彬 张峰 王轶 邹晓平

张玮, 诸葛宇征, 张明, 贺奇彬, 张峰, 王轶, 邹晓平. 经颈静脉肝内门体分流术治疗原发性胆汁性肝硬化门静脉高压的效果及安全性[J]. 临床肝胆病杂志, 2016, 32(2): 259-263. DOI: 10.3969/j.issn.1001-5256.2016.02.012
引用本文: 张玮, 诸葛宇征, 张明, 贺奇彬, 张峰, 王轶, 邹晓平. 经颈静脉肝内门体分流术治疗原发性胆汁性肝硬化门静脉高压的效果及安全性[J]. 临床肝胆病杂志, 2016, 32(2): 259-263. DOI: 10.3969/j.issn.1001-5256.2016.02.012
Zhang Wei, ZhuGe YuZheng, Zhang Ming, He QiBin, Zhang Feng, Wang Yi, Zou XiaoPing. Therapeutic effect and safety of transjugular intrahepatic portosystemic shunt in patients with primary biliary cirrhosis and portal hypertension[J]. J Clin Hepatol, 2016, 32(2): 259-263. DOI: 10.3969/j.issn.1001-5256.2016.02.012
Citation: Zhang Wei, ZhuGe YuZheng, Zhang Ming, He QiBin, Zhang Feng, Wang Yi, Zou XiaoPing. Therapeutic effect and safety of transjugular intrahepatic portosystemic shunt in patients with primary biliary cirrhosis and portal hypertension[J]. J Clin Hepatol, 2016, 32(2): 259-263. DOI: 10.3969/j.issn.1001-5256.2016.02.012

经颈静脉肝内门体分流术治疗原发性胆汁性肝硬化门静脉高压的效果及安全性

DOI: 10.3969/j.issn.1001-5256.2016.02.012
详细信息
  • 中图分类号: R575.2

Therapeutic effect and safety of transjugular intrahepatic portosystemic shunt in patients with primary biliary cirrhosis and portal hypertension

  • 摘要:

    目的探讨经颈静脉肝内门体分流术(TIPS)应用于失代偿期原发性胆汁性肝硬化(PBC)患者的短期疗效及安全性。方法对2009年1月-2015年5月于南京大学医学院附属鼓楼医院行TIPS治疗的26例失代偿期PBC患者的临床数据进行回顾性分析。对比术前术后门静脉压力、肝功能、生存率等指标及术后1年的随访情况。用Friedman检验进行多个相关样本的秩和检验,Wilcoxon检验进行配对秩和检验,对整个随访期内患者生存率作Kaplan-Meier分析曲线。结果 26例患者术后平均门静脉压力为19.11(16.3522.05)mm Hg,较术前27.93(25.2630.87)mm Hg显著下降,差异具有统计学意义(Z=-4.199,P<0.001)。术后3个月内TBil、终末期肝病模型评分、胆汁酸等较术前明显上升(χ2值分别为26.000、18.429、16.353,P值均<0.001)。术后最常见并发症为发热,发生率为80.77%(21/26),其次为肝性脑病,发生率为19.23%(7/26),术后6、12个月生存率均为92.3%(24...

     

  • [1]CAREY EJ,ALI AH,LINDOR KD.Primary biliary cirrhosis[J].Lancet,2015,386(10003):1565-1575.
    [2]RUDLER M,CLUZEL P,CORVEC TL,et al.Early-TIPSS placement prevents rebleeding in high-risk patients with variceal bleeding,without improving survival[J].Aliment Pharmacol Ther,2014,40(9):1074-1080.
    [3]GARCIA-PAGAN JC,CACA K,BUREAU C,et al.Early use of TIPS in patients with cirrhosis and variceal bleeding[J].N Engl J Med,2010,362(25):2370-2379.
    [4]CHENG SP,XUE HL,ZENG WZ,et al.TIPS for treatment of gastro-intestinal bleeding in patients with liver cirrhosis:Analysis of232 cases[J].World Chin J Dig,2014,22(15):2163-2168.(in Chinese)程双平,薛红利,曾维政,等.TIPS手术治疗肝硬化消化系出血232例[J].世界华人消化杂志,2014,22(15):2163-2168.
    [5]HEATHCOTE EJ.Management of primary biliary cirrhosis.The American Association for the Study of Liver Diseases practice guidelines[J].Hepatology,2000,31(4):1005-1013.
    [6]QI X,LIU L,BAI M,et al.Transjugular intrahepatic portosystemic shunt in combination with or without variceal embolization for the prevention of variceal rebleeding:a meta-analysis[J].J Gastroenterol Hepatol,2014,29(4):688-696.
    [7]LI CQ,LI HL,GUO J,et al.Application of simulative viatorr technique in TIPS with double stents[J/CD].Chin J Liver Dis:Electronic Edition,2014,6(1):50-54.(in Chinese)李常青,李洪璐,郭江,等.双支架技术在TIPS治疗中的临床应用研究[J/CD].中国肝脏病杂志:电子版,2014,6(1):50-54.
    [8]PERARNAU JM,LE GOUGE A,NICOLAS C,et al.Covered vs.uncovered stents for transjugular intrahepatic portosystemic shunt:a randomized controlled trial[J].J Hepatol,2014,60(5):962-968.
    [9]LUCA A,MIRAGLIA R,CARUSO S,et al.Short-and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis[J].Gut,2011,60(6):846-852.
    [10]YUAN SS.Long-term outcome and predictors of mortality after transjugular intrahepatic portosystemic shunt(TIPS)for variceal hemorrhage and refractory ascites[D].Xi'an:Fourth Military Medical University,2011.(in Chinese)原姗姗.TIPS治疗肝硬化静脉曲张出血和顽固性腹水的长期疗效和预后分析[D].西安:第四军医大学,2011.
    [11]TRIPATHI D,LUI HF,HELMY A,et al.Randomised controlled trial of long term portographic follow up versus variceal band ligation following transjugular intrahepatic portosystemic stent shunt for preventing oesophageal variceal rebleeding[J].Gut,2004,53(3):431-437.
    [12]CASADABAN LC,PARVINIAN A,COUTURE PM,et al.Characterization of liver function parameter alterations after transjugular intrahepatic portosystemic shunt creation and association with early mortality[J].AJR Am J Roentgenol,2014,203(6):1363-1370.
    [13]LAMMERS WJ,van BUUREN HR,HIRSCHFIELD GM,et al.Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis:an international follow-up study[J].Gastroenterology,2014,147(6):1338-1349.
    [14]CASADABAN LC,PARVINIAN A,MINOCHA J,et al.Clearing the confusion over hepatic encephalopathy after TIPS creation:incidence,prognostic factors,and clinical outcomes[J].Dig Dis Sci,2015,60(4):1059-1066.
    [15]RIGGIO O,NARDELLI S,MOSCUCCI F,et al.Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J].Clin Liver Dis,2012,16(1):133-146.
  • 加载中
计量
  • 文章访问数:  42
  • HTML全文浏览量:  7
  • PDF下载量:  124
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-12-09
  • 出版日期:  2016-02-20
  • 刊出日期:  2016-02-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回